Bacteremia in Patients with Autologous and Allogeneic Hematopoietic Stem Cell Transplantation:

Clinical Features, Resistance Patterns, and **Risk Factors for Mortality**

Herrera F¹, Laborde A², Jordán R³, Berruezo L⁴, Roccia Rossi I⁵, Mañez N⁶, Lambert S⁷, Pereyra M⁸, Nenna A⁹, Dictar M¹⁰, Costantini P¹¹, Benso J¹², Carena A¹, Gonzalez Ibañez M², Eusebio M³, Baldoni N⁴, Lovano F⁵, Barcán L⁶, Tula L⁷, Racioppi A¹⁰, Luck M¹¹, Pasterán F¹³, Corso A¹³, Rapoport M¹³, Nicola F¹, García Damiano M², Monge R³, Carbone R⁴, Reynaldi M⁵, Greco G⁶, Blanco M⁷, Vilches V⁸, Chaves M⁹, Valle S¹⁰, Bronzi M¹¹, Torres D¹.

The Argentine Group for the Study of Bacteremia in Cancer and Stem Cell Transplant



- 1. Hospital Universitario CEMIC, 2. FUNDALEU, 3. Hospital Británico de Buenos Aires,
- 4. HIGA Dr. Rodolfo Rossi, 5. HIGA San Martín, 6. Hospital Italiano de Buenos Aires,
- 7. Hospital "El Cruce" Alta Complejidad en Red, 8. Hospital Universitario Austral,
- 9. Hospital Municipal de Oncología Marie Curie, 10. Instituto Alexander Fleming,
- 11. Hospital de Oncología Angel Roffo, 12. Hospital Italiano de Buenos Aires (San Justo), 13. INEI-ANLIS Dr. Carlos Malbrán

Buenos Aires - Argentina

Disclosures

- Dr. Fabián Herrera:
 - Speaker and advisory board:
 - Pfizer
 - MSD
 - Education and research grant:
 - Pfizer
- Dr. Alberto Carena:



Background

- Clinical and microbiologic characteristic of bacteremia in patients with hematopoietic stem cell transplantation (HSCT) may differ according to the type of transplant.
- Our purpose was to describe and compare the clinical features of bacteremia episodes in patients with HSCT, as well as resistance patterns of gram-negative bacteremia (GNB) between autologous and allogeneic HSCT and identify risk factors for 30-day mortality.



Methods

- Prospective, observational, and multicenter study carried out in 12 centers of Argentina from May 2014 to July 2021.
- The first episodes of bacteremia during hospitalization in adult patients with HSCT were included.
- Clinical features, microbiological characteristics, resistance profile in GNB and outcome were compared between autologous or allogeneic HSCT.
- To identify risk factors for 30-day mortality we performed a logistic regression model for multivariate analysis.



Results: Baseline Characteristics


391 episodes were included: Auto 212 vs. Allo 179

	Auto-HSCT	Allo-HSCT	р
Age - Median (IQR)	52 (47-63)	41 (31-51)	<0.0001
Charlson Score – Median (IQR)	2 (2-2)	2 (2-2)	0.94
Underlying disease – n (%)			
Acute Leukemia	0	117 (65.4)	<0.0001
Lymphoma	111 (52.3)	24 (13.4)	<0.0001
Multiple Myeloma	98 (46.2)	2 (1.1)	<0.0001
Myelodysplastic syndromes	1 (0.5)	29 (16.2)	<0.0001
Neutropenia - n (%)	182 (85.5)	128 (71.5)	<0.0001
Duration (days) – Median (IQR)	11 (9-14)	18 (12-27)	<0.0001
Status of disease – n (%)			
Complete remission	129 (60.8)	108 (60.3)	0.917
Partial remission	47 (22.2)	13 (7.3)	<0.0001
Relapse	28 (13.2)	38 (21.2)	0.035
Refractory	8 (3.4)	20 (11.2)	0.005



Results: Clinical Features

Clinical Source




Severity of presentation	Auto-HSCT	Allo-HSCT	р
ICU admission – n (%)	33 (15.6)	41 (22.9)	0.065
Shock – n (%)	30 (14.1)	39 (21.7)	0.048
Pitt Score – Median (IQR)	0 (0-2)	0 (0-2)	0.508
APACHE II Score – Median (IQR)	13 (10-17)	14 (10-16)	0.446




Results: Microbiological Isolates

Gram-Negative Bacilli




Gram-Positive Cocci





Results: Resistance Profile in GNB




Results: 30-day Mortality

Auto-HSCT 13.2% vs. **Allo-HSCT** 25.1%

Survival

Risk factors for Mortality



	MV analysis OR (95%CI)	p
Relapse underlying disease	5 (1.4-18)	0.01
Carbapenem resistant GNB	3.4 (1-11)	0.04
Shock	13.6 (1.7-108)	0.001



Conclusion

- Allogeneic-HSCT patients had GNB bacteremia more frequently than autologous-HSCT with higher resistance patterns.
- They also had higher severity and mortality.
- Our results stress the importance of infection control measures and antibiotic stewardship to reduce resistance and mortality in this population.



Thanks!

http://registrorocas.com.ar/es/home/

